Amgen narrows neuro focus to inflammation

Despite early success for Amgen’s first marketed neurology product, the company will exit research and early development for neuroscience, narrowing its focus to neuroinflammation.

“To compete effectively, we need to make investments in the areas and platforms that will position us for long-term success,” David Reese, EVP of R&D at Amgen Inc.

Read the full 516 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers